Merck & Company Inc (MRK)vsVir Biotechnology Inc (VIR)
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
VIR
Vir Biotechnology Inc
$8.77
+0.34%
HEALTHCARE · Cap: $1.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 100317% more annual revenue ($65.77B vs $65.50M). MRK leads profitability with a 13.6% profit margin vs 0.0%. VIR earns a higher WallStSmart Score of 56/100 (C).
MRK
Hold50
out of 100
Grade: D+
VIR
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for VIR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Strong operational efficiency at 459241.0%
Revenue surging 417.8% year-over-year
Earnings expanding 58.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -47.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : VIR
The strongest argument for VIR centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 417.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : VIR
The primary concerns for VIR are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while VIR is a hypergrowth play — different risk/reward profiles.
VIR carries more volatility with a beta of 1.64 — expect wider price swings.
VIR is growing revenue faster at 417.8% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
VIR scores higher overall (56/100 vs 50/100) and 417.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vir Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?